Skip to main content

Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria

Journal of Pharmacokinetics and Pharmacodynamics volume 34, pages 669–686 (2007)Cite this article

Abstract

The study aimed to characterize the population pharmacokinetics of amodiaquine (AQ) and its major metabolite N-desethylamodiaquine (N-DEAQ), and to assess the correlation between exposure to N-DEAQ and treatment outcome. Blood samples from children in two studies in Zanzibar and one in Papua New Guinea were included in the pharmacokinetic analysis (n = 86). The children had been treated with AQ in combination with artesunate or sulphadoxine-pyrimethamine. The population pharmacokinetics of AQ and N-DEAQ were modeled using the non-linear mixed effects approach as implemented in NONMEM. Bayesian post-hoc estimates of individual pharmacokinetic parameters were used to generate individual profiles of N-DEAQ exposure. The correlation between N-DEAQ exposure and effect was studied in 212 patients and modeled with logistic regression in NONMEM. The pharmacokinetics of AQ and N-DEAQ were best described by two parallel two-compartment models with a central and a peripheral compartment for each compound. The systemic exposure to AQ was low in comparison to N-DEAQ. The t 1/2λ of N-DEAQ ranged from 3 days to 12 days. There was a statistically significant, yet weak, association between N-DEAQ concentration on day 7 and treatment outcome. The age-based dosing schedule currently recommended in Zanzibar appeared to result in inadequate exposure to N-DEAQ in many patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Murphy SC and Breman JG (2001). Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia and complications of pregnancy. Am J Trop Med Hyg 64(1–2 Suppl): 57–67

    PubMed  CAS  Google Scholar 

  2. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M and Masimirembwa CM (2002). Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300(2): 399–407

    PubMed  Article  CAS  Google Scholar 

  3. Pussard E, Verdier F, Faurisson F, Scherrmann JM, Le Bras J and Blayo MC (1987). Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur J Clin Pharmacol 33(4): 409–414

    PubMed  Article  CAS  Google Scholar 

  4. Winstanley P, Edwards G, Orme M and Breckenridge A (1987). The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol 23(1): 1–7

    PubMed  CAS  Google Scholar 

  5. Winstanley PA, Simooya O, Kofi-Ekue JM, Walker O, Salako LA, Edwards G, Orme ML and Breckenridge AM (1990). The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol 29(6): 695–701

    PubMed  CAS  Google Scholar 

  6. White NJ, Looareesuwan S, Edwards G, Phillips RE, Karbwang J, Nicholl DD, Bunch C and Warrell DA (1987). Pharmacokinetics of intravenous amodiaquine. Br J Clin Pharmacol 23(2): 127–135

    PubMed  CAS  Google Scholar 

  7. Laurent F, Saivin S, Chretien P, Magnaval JF, Peyron F, Sqalli A, Tufenkji AE, Coulais Y, Baba H and Campistron G (1993). Pharmacokinetic and pharmacodynamic study of amodiaquine and its two metabolites after a single oral dose in human volunteers. Arzneimittelforschung 43(5): 612–616

    PubMed  CAS  Google Scholar 

  8. Gerstner U, Prajakwong S, Wiedermann G, Sirichaisinthop J, Wernsdorfer G and Wernsdorfer WH (2003). Comparison of the in-vitro activity of amodiaquine and its main metabolite, monodesethyl-amodiaquine, in Plasmodium falciparum. Wien Klin Wochenschr 115(Suppl 3): 33–38

    PubMed  CAS  Google Scholar 

  9. Childs GE, Boudreau EF, Milhous WK, Wimonwattratee T, Pooyindee N, Pang L and Davidson DE (1989). A comparison of the in vitro activities of amodiaquine and desethylamodiaquine against isolates of Plasmodium falciparum. Am J Trop Med Hyg 40(1): 7–11

    PubMed  CAS  Google Scholar 

  10. Mariga ST, Gil JP, Sisowath C, Wernsdorfer WH and Bjorkman A (2004). Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 48(11): 4089–4096

    PubMed  Article  CAS  Google Scholar 

  11. Aubouy A, Bakary M, Keundjian A, Mbomat B, Makita JR, Migot-Nabias F, Cot M, Le Bras J and Deloron P (2003). Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother 47(1): 231–237

    PubMed  Article  CAS  Google Scholar 

  12. Hombhanje FW, Hwaihwanje I, Tsukahara T, Saruwatari J, Nakagawa M, Osawa H, Paniu MM, Takahashi N, Lum JK, Aumora B, Masta A, Sapuri M, Kobayakawa T, Kaneko A and Ishizaki T (2005). The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br J Clin Pharmacol 59(3): 298–301

    PubMed  Article  CAS  Google Scholar 

  13. Lindegårdh N, Forslund M, Green MD, Kaneko A and Bergqvist Y (2002). Automated solid-phase extraction for determination of amodiaquine, chloroquine and metabolites in Capillary blood on sampling paper by liquid chromatography. Chromatographia 55: 5–12

    Article  Google Scholar 

  14. Jonsson EN and Karlsson MO (1999). Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58(1): 51–64

    PubMed  Article  CAS  Google Scholar 

  15. Beal SL and Sheiner LB (1982). Estimating population kinetics. Crit Rev Biomed Eng 8(3): 195–222

    PubMed  CAS  Google Scholar 

  16. Wahlby U, Jonsson EN and Karlsson MO (2001). Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28(3): 231–252

    PubMed  Article  CAS  Google Scholar 

  17. Gobburu JV and Lawrence J (2002). Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences. Pharm Res 19(1): 92–98

    PubMed  Article  CAS  Google Scholar 

  18. Holford N (2005) A degenerative predictive check. In: 14th P.A.G.E. Meeting. Pamplona

  19. Montgomery DC, Peck EA and Vining GG (2001). Introduction to linear regression analysis. Wiley, Chichester, New York

    Google Scholar 

  20. Holford N (2007) Wings for NONMEM Version 600. Accessed: April 2007

  21. Mihaly GW, Nicholl DD, Edwards G, Ward SA, Orme ML, Warrell DA and Breckenridge AM (1985). High-performance liquid chromatographic analysis of amodiaquine in human plasma. J Chromatogr 337(1): 166–171

    PubMed  CAS  Google Scholar 

  22. Wennerholm A, Nordmark A, Pihlsgard M, Mahindi M, Bertilsson L and Gustafsson LL (2006). Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. Eur J Clin Pharmacol 62(7): 539–546

    PubMed  Article  CAS  Google Scholar 

  23. Rowland M and Tozer TN (1995). Clinical pharmacokinetics: concepts and applications. Williams and Wilkins, USA

    Google Scholar 

  24. Guidelines for the treatment of malaria/ World Health Organization 2006

  25. Taylor WR, Terlouw DJ, Olliaro PL, White NJ, Brasseur P and ter Kuile FO (2006). Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull World Health Organ 84(12): 956–964

    PubMed  Article  Google Scholar 

  26. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS and Bjorkman A (2005). Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 41(8): 1079–1086

    PubMed  Article  CAS  Google Scholar 

  27. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G and Staedke SG (2006). Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials 1(1): e7

    PubMed  Article  Google Scholar 

  28. Eggelte TA, Agtmael MA and Boxtel CJ (1999). Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci 20(5): 199–205

    PubMed  Article  Google Scholar 

  29. Taylor WR, Rigal J and Olliaro PL (2003). Drug resistant falciparum malaria and the use of artesunate-based combinations: focus on clinical trials sponsored by TDR. J Vector Borne Dis 40(3–4): 65–72

    PubMed  CAS  Google Scholar 

  30. Borrmann S, Adegnika AA, Missinou MA, Binder RK, Issifou S, Schindler A, Matsiegui PB, Kun JF, Krishna S, Lell B and Kremsner PG (2003). Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon. Antimicrob Agents Chemother 47(3): 901–904

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at Göteborg University, Box 431, Göteborg, 405 30, Sweden

    Sofia Friberg Hietala, Daniel Röshammar & Michael Ashton

  2. Malaria Research Unit, Unit for Infectious Diseases, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden

    Achuyt Bhattarai, Johan Strömberg, Akira Kaneko & Anders Björkman

  3. Zanzibar Malaria Control Program, Zanzibar, Tanzania

    Mwinyi Msellem & Abdullah S. Ali

  4. Department of International Affairs and Tropical Medicine, Tokyo Women’s Medical University, Tokyo, Japan

    Akira Kaneko

  5. Faculty of Health Sciences, Divine Word University, Madang, Papua New Guinea

    Francis W. Hombhanje

Authors
  1. Sofia Friberg Hietala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Achuyt Bhattarai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mwinyi Msellem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Röshammar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abdullah S. Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Johan Strömberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francis W. Hombhanje
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akira Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Anders Björkman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michael Ashton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Ashton.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hietala, S.F., Bhattarai, A., Msellem, M. et al. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn 34, 669–686 (2007). https://doi.org/10.1007/s10928-007-9064-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-007-9064-2

Keywords

  • Amodiaquine
  • Desethylamodiaquine
  • Malaria
  • Child
  • Population pharmacokinetic/pharmacodynamic modeling